GPPAD-POInT
Research type
Research Study
Full title
GPPAD-POInT (Global Platform of Autoimmune Diabetes – Primary Oral Insulin Trial)\n\nOral Insulin Therapy for Prevention of Autoimmune Diabetes
IRAS ID
237301
Contact name
Matthew Snape
Contact email
Sponsor organisation
Technische Universität München, Represented by the school of medicine
Eudract number
2017-003088-36
Clinicaltrials.gov Identifier
Duration of Study in the UK
7 years, 6 months, 31 days
Research summary
Type 1 diabetes (T1D) is an immune-mediated disease in which insulin-producing betacells are completely or near completely destroyed, resulting in life-long dependence on exogenous insulin. It is a chronic and potentially disabling disease that represents a major public health and clinical concern. The number of patients diagnosed with T1D each year is increasing and is approaching an epidemic level in some countries that track this information\n\nThe POInT study examines whether the development of T1D can be prevented in children with an increased risk of T1D through preventive treatment with insulin. Infants who have a high risk of developing type 1 diabetes will be identified in the INGR1D screening study and will then be invited to take part in the POInT study. In POInT, insulin will be given to children aged between 4-7 months every day until their 3rd birthday to see if it reduces the incidence of diabetes in childhood. The insulin will be given orally (via mouth) as a powder and is not used to lower blood glucose levels. Instead, it serves to train and regulate the immune system. \n
REC name
South Central - Oxford A Research Ethics Committee
REC reference
18/SC/0019
Date of REC Opinion
4 Apr 2018
REC opinion
Further Information Favourable Opinion